Sports
FDA Approves Merck's KEYTRUDA + Padcev Regimens For Muscle-Invasive Bladder Cancer
(RTTNews) - Merck & Co Inc. (MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), the company's anti-PD-1 therapi…